

**SUB C4**  
<sup>36</sup>37. (New) A pharmaceutical composition comprising the hSP of claim <sup>27</sup>28 together with a pharmaceutically acceptable carrier or excipient.

<sup>37</sup>38. (New) A method for the treatment of gastrointestinal disorders, comprising administering the pharmaceutical composition of claim <sup>36</sup>37.

<sup>38</sup>39. (New) The method of claim <sup>35</sup>36, wherein the host cell is a *Saccharomyces cerevisiae* or *Aspergillus oryzae*.


---

#### REMARKS

This amendment is submitted to cancel claims 1-27 and present new claims 28-39. No new matter added, and entry of the amendment is respectfully requested.

Respectfully submitted,

Date: 17 March 2000

  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123